Get the Stockscreener App
12.80
3.54%
-0.47
After Hours:
12.81
0.010
+0.08%
Wave Life Sciences Ltd stock is traded at $12.80, with a volume of 3.20M.
It is down -3.54% in the last 24 hours and down -7.98% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$13.27
Open:
$13.19
24h Volume:
3.20M
Relative Volume:
0.49
Market Cap:
$2.38B
Revenue:
$93.95M
Net Income/Loss:
$-129.87M
P/E Ratio:
-14.22
EPS:
-0.9
Net Cash Flow:
$-202.88M
1W Performance:
+0.39%
1M Performance:
-7.98%
6M Performance:
+51.48%
1Y Performance:
+17.32%
1-Day Range:
$12.51
$13.23
1-Week Range:
$12.51
$14.15
52-Week Range:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
12.80 | 2.47B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
WAVE Life Sciences (NASDAQ:WVE) Given New $27.00 Price Target at Wells Fargo & Company - MarketBeat
WVE Stock Update: Wells Fargo Adjusts Price Target Amidst Steady Ratings | WVE Stock News - GuruFocus
Paul Bolno Sells 10,480 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock - MarketBeat
Kyle Moran Sells 3,588 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
(02/11/26) Top Picks 2026: Wave Life Sciences Ltd. (WVE) - moneyshow.com
Published on: 2026-02-10 01:59:11 - baoquankhu1.vn
Wave Life Sciences (WVE) regains rights to potential rare genetic disorder treatment - MSN
The Bull Case For Wave Life Sciences (WVE) Could Change Following WVE-006 Rights Reversion And FDA Talks - Yahoo Finance
Assessing Wave Life Sciences (WVE) Valuation After A 7x Three Year Total Return - Yahoo Finance
Why The Wave Life Sciences WVE Story Is Shifting After New RNA And AATD Updates - Yahoo Finance
Will Regaining Full Rights to WVE-006 and Pursuing FDA Fast Track Change Wave Life Sciences' (WVE) Narrative - simplywall.st
How (WVE) Movements Inform Risk Allocation Models - Stock Traders Daily
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment - Finviz
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Wave Life Sciences receives back rights to AATD therapy from GSK - MSN
13 Best Revenue Growth Stocks to Buy Right Now - Insider Monkey
WAVE Life Sciences (NASDAQ:WVE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
WAVE Life Sciences (NASDAQ:WVE) Now Covered by Bank of America - MarketBeat
WVE Sees Analyst Rating Boost with Raised Price Target | WVE Stock News - GuruFocus
Assessing Wave Life Sciences (WVE) Valuation After Regaining Global Rights To WVE-006 From GSK - Sahm
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Wave Life Sciences (WVE) and Arcellx Inc (ACLX) - The Globe and Mail
Wave Life Sciences Ltd. (WVE): Analyst Consensus Highlights 143.73% Potential Upside for Biotech Innovator - DirectorsTalk Interviews
Wave Life Sciences price target raised to $50 from $47 at Clear Street - Yahoo Finance
WVE Sees Price Target Boost: Canaccord Genuity Adjusts to $43.00 - GuruFocus
Wave Life Sciences Regains Full Rights to WVE-006 from GSK - intellectia.ai
WAVE Life Sciences stock price target raised to $43 from $40 at Canaccord - Investing.com Australia
WAVE Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com India
Wave Life Sciences regains rights to AATD therapy WVE-006 from GSK - Investing.com Nigeria
Wave Life Sciences regains rights to AATD therapy WVE-006 from GSK By Investing.com - Investing.com South Africa
WAVE Life Sciences stock rating reiterated by Raymond James on regained drug rights - Investing.com Australia
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
Clear Street raises WAVE Life Sciences stock price target to $50 on AATD program - Investing.com Nigeria
Wave Life Sciences stock rises after regaining full rights to AATD therapy By Investing.com - Investing.com South Africa
Wave Life Sciences stock rises after regaining full rights to AATD therapy - Investing.com India
Wave Life Sciences (WVE) Reclaims Rights to AATD Asset WVE-006 - GuruFocus
Wave Life Sciences plans to accelerate regulatory engagement with full control of WVE-006 - marketscreener.com
Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path - TipRanks
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - The Manila Times
Wave Life Sciences Ltd Accelerates Regulatory Engagement for WVE-006 - TradingView
Wave RNA drug for rare lung and liver disease heads for FDA talks - Stock Titan
How Investors May Respond To Wave Life Sciences (WVE) Expanding PRISM RNA Platform Via Big-Pharma Partnerships - Sahm
Market Outlook: Does CBTJ stock reflect fundamentalsJuly 2025 Volume & High Accuracy Investment Entry Signals - baoquankhu1.vn
Federated Hermes Inc. Has $27.46 Million Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
WAVE Life Sciences (NASDAQ:WVE) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Wave Life Sciences Ltd. (WVE) Growth Potential: Analysts Predict 141% Upside - DirectorsTalk Interviews
Trading Systems Reacting to (WVE) Volatility - Stock Traders Daily
Aug Outlook: Will Standard BioTools Inc stock recover after earningsPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Buyback Watch: Will Wave Life Sciences Ltd outperform small cap indexes2025 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
Moving Averages: Is Wave Life Sciences Ltd stock suitable for long term investingWeekly Stock Report & Advanced Technical Signal Analysis - baoquankhu1.vn
Emerald Mutual Fund Advisers Trust Sells 171,427 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):